Key Highlights

  • Enlivex Ltd. (NASDAQ:ENLV) was quoted at USD 2.50, down 7.41%, in pre-market trading on Wednesday, October 28, 2026, the first full session after a 1-for-16 reverse share split took effect on Tuesday, October 27, 2026.
  • The release of Monday, October 19, 2026 set out a cost reduction plan with a workforce cut of about 60%. Enlivex (NASDAQ:ENLV) expects six-month topline data from its Phase 2b knee osteoarthritis trial by mid-2027.
  • The reverse split cut outstanding shares from 24,511,905 to about 1,531,995, and the company ended a securities purchase agreement with the Rain Foundation on Tuesday, September 22, 2026.
  • The share price reflects a recent split and thin trading, and the October releases did not state a net loss or cash balance.

The Pre-Market Move and Its Trigger

Enlivex Ltd. (NASDAQ:ENLV) is a clinical-stage immunotherapy company developing Allocetra for age-related osteoarthritis. It also runs a treasury strategy built around the Rain prediction market protocol. The shares traded at USD 2.50 in the Wednesday, October 28, 2026 pre-market, a 7.41% fall. The company's release of Thursday, October 22, 2026 announced the 1-for-16 reverse split, which took effect on Tuesday, October 27, 2026, so the quote is split adjusted. Thin trading in a share count of about 1.5 million fits the move, an inference.

How the October Releases Read

The release of Monday, October 19, 2026 described a plan to wind down research unrelated to the Phase 2b Allocetra trial in knee osteoarthritis and to cut the workforce by about 60%. Management salaries fall by 20% and the chief executive's by 40%, and six-month topline data are expected by mid-2027. The release of Thursday, October 22, 2026 reduced authorised shares from 158,333,333 to 9,895,833 and raised par value from NIS 6.00 to NIS 96.00. Earlier, Enlivex received Regenerative Medicine Advanced Therapy designation for Allocetra and carried out a 1-for-15 reverse split on Thursday, July 9, 2026.

Risks and What to Watch

The optimistic reading is that the cost plan concentrates money on the one asset with a regulatory designation and stretches the funding runway, while the reverse split props up the quoted price. The pessimistic reading is that two reverse splits in four months, a 60% cut to the workforce and the end of the Rain Foundation deal point to financing strain. Dilution from future raises, trial delays or failure, and swings in the value of the Rain-linked holdings are named risks. A private placement of about USD 400 million, announced Tuesday, July 28, 2026, needed shareholder approval, and the October releases do not say where that stands. Watch the next financial report, any trial update before mid-2027 and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

Enlivex Ltd. (NASDAQ:ENLV) slid 7.41% before the open on the first full session after its reverse split, with no fresh announcement that day. The shrinking share count and the cost programme are the context. The key figure is the cut in outstanding shares to about 1,531,995. Upcoming catalysts are the next financial report, the Federal Reserve decision later on Wednesday, October 28, 2026 and trial data by mid-2027. Pre-market prices are snapshots that can change, and this is not investment advice.